BMX Kinase-Mediated ATP6V1E1 Phosphorylation Enables Mtb Survival

Study Background and Research Question

Mycobacterium tuberculosis (Mtb) remains a formidable global health threat, responsible for an estimated 10.8 million new tuberculosis (TB) cases and 1.25 million deaths in 2024, as reported by the WHO. Despite advances in TB management, Mtb's capacity to persist within host macrophages underpins the chronicity and recurrence of infection. Upon phagocytosis, Mtb-containing phagosomes typically mature through fusion with lysosomes, resulting in acidification and the activation of degradative hydrolases crucial for pathogen clearance. However, Mtb has evolved multiple mechanisms to circumvent this fate, primarily by disrupting phagosome maturation and lysosomal acidification. While several mycobacterial factors interfering with lysosome fusion have been identified, the precise molecular mechanisms by which Mtb suppresses lysosomal acidification have remained less clear. The central research question of the current study is: How does Mtb manipulate host cell machinery to inhibit lysosomal acidification and promote its intracellular survival?

Key Innovation from the Reference Study

The reference study (Chen et al., 2026) introduces a previously unrecognized mechanism by which Mtb modulates host cell signaling to evade lysosomal degradation. The authors discovered that the Mtb-secreted acyltransferase Chp2 (Rv1184) directly targets the host vacuolar ATPase (V-ATPase) complex by promoting phosphorylation of its E1 subunit, ATP6V1E1, at tyrosine residues Tyr56/57. This phosphorylation event, facilitated by the host tyrosine kinase BMX, impairs V-ATPase assembly and function, thereby preventing effective lysosomal acidification. Notably, Chp2 increases BMX-dependent phosphorylation of ATP6V1E1 by physically bridging BMX and ATP6V1E1, enabling Mtb to persist within a non-acidified intracellular compartment. The study further demonstrates that pharmacological inhibition or genetic knockdown of BMX disrupts this process, impairing Mtb survival in both macrophage cultures and in vivo mouse models.

Methods and Experimental Design Insights

The investigators employed a combination of molecular, biochemical, and cellular approaches to delineate the pathway by which Mtb interferes with host lysosomal acidification. Key methodological elements included:

• Secretome Screening: Systematic screening of Mtb-secreted proteins was performed to identify candidates capable of inhibiting lysosomal acidification in host macrophages.
• Protein Interaction and Phosphorylation Assays: Co-immunoprecipitation and in vitro kinase assays established direct interactions among Chp2, ATP6V1E1, and BMX, and determined the specific phosphorylation sites on ATP6V1E1.
• Cellular Functional Assays: Fluorescent pH-sensitive probes and V-ATPase assembly assays quantified lysosomal acidification and V-ATPase functionality in macrophages infected with wild-type or mutant Mtb strains.
• Genetic and Pharmacological Manipulation: BMX expression was silenced via siRNA or inhibited using small-molecule BMX kinase inhibitors to assess the impact on ATP6V1E1 phosphorylation and Mtb survival.
• In Vivo Validation: Murine infection models confirmed the relevance of the BMX–ATP6V1E1 axis in supporting Mtb persistence in host tissues.

Core Findings and Why They Matter

The core findings of the study are as follows:

• Chp2-Dependent BMX Recruitment: The Mtb-secreted protein Chp2 binds ATP6V1E1 and enhances its interaction with the host tyrosine kinase BMX, resulting in increased phosphorylation at Tyr56/57.
• Phosphorylation Inhibits V-ATPase Assembly: Phosphorylated ATP6V1E1 disrupts the proper assembly of the V-ATPase complex, leading to impaired lysosomal acidification necessary for effective pathogen degradation.
• Host Kinase as a Vulnerability: Genetic silencing or pharmacological inhibition of BMX restores lysosomal acidification and significantly reduces Mtb survival both in vitro and in vivo (Chen et al., 2026).

These results highlight BMX kinase as a critical mediator of Mtb immune evasion and identify the host kinase–V-ATPase axis as a potential target for host-directed TB therapies. The work also reinforces the broader significance of lysosomal acidification in cellular defense, with implications for aging, neurodegeneration, and cancer biology.

Comparison with Existing Internal Articles

Several internal articles contextualize these findings within the broader landscape of BMX kinase research. For example, "BMX Kinase-Driven ATP6V1E1 Phosphorylation Enables Mtb Survival" discusses the same pathway, emphasizing the host-pathogen interaction and therapeutic implications. Another resource, "BMX-IN-1: Unlocking BMX Kinase Inhibition for Host-Pathogen Research", explores the utility of BMX kinase inhibitors in dissecting the role of BMX in lysosomal acidification, bridging oncology and infectious disease models. Additionally, "BMX-IN-1: Selective BMX Kinase Inhibitor for Cancer & TB Models" provides benchmarking data for BMX-IN-1 in both cancer and TB-related assays, highlighting the cross-domain relevance of BMX kinase targeting. These resources collectively indicate a growing recognition of BMX kinase's dual role in oncogenic signaling and immune evasion by pathogens.

Limitations and Transferability

While the study establishes a compelling mechanistic link between Mtb-secreted Chp2, host BMX kinase activity, and impaired lysosomal acidification, several limitations merit consideration:

• Model System Constraints: Most experiments were performed in murine macrophages or mouse infection models; the relevance to human TB pathogenesis requires further validation.
• Specificity of BMX Inhibition: Although BMX silencing or inhibition restricted Mtb survival, potential off-target effects and the impact on host immune function were not exhaustively explored.
• Broader Implications: The degree to which other pathogens exploit similar host kinase-lysosomal pathways remains to be determined, as does the long-term safety of systemic BMX inhibition.

Nonetheless, the findings provide a strong foundation for future studies into host-directed TB therapies and suggest BMX kinase as a promising target for modulating lysosomal function in disease.

Protocol Parameters

• Mtb infection model: Infect murine or human macrophages with Mtb at a multiplicity of infection (MOI) of 1–5; monitor phagosome maturation and acidification 24–48 hours post-infection.
• BMX kinase inhibition: Apply small-molecule inhibitors or siRNA silencing of BMX prior to or shortly after Mtb infection to assess effects on ATP6V1E1 phosphorylation and lysosomal acidification.
• Lysosomal pH measurement: Use LysoSensor or similar fluorescent pH probes to quantify acidification in macrophage lysosomes following treatments.
• Phosphorylation site mutation assay: Express ATP6V1E1 mutants lacking Tyr56/57 phosphorylation sites to confirm functional consequences on V-ATPase assembly.
• In vivo validation: Treat infected mice with BMX kinase inhibitors and assess bacterial burden and lysosomal function in lung tissue samples.

Researchers should optimize inhibitor concentrations and exposure times for their specific cellular system, as literature reports that BMX kinase inhibition can modulate cell cycle progression and apoptosis in various models (product information).

Why this cross-domain matters, maturity, and limitations

The identification of BMX kinase as a convergence point between cancer cell biology (e.g., apoptosis induction in cancer cells, cell cycle arrest at G0/G1 phase) and host-pathogen interactions significantly broadens the scope of BMX kinase research. BMX has established roles in oncogenesis—particularly in prostate cancer research and B-cell lymphoma research—but its involvement in immune evasion by Mtb highlights the potential for cross-domain therapeutic strategies (see host-pathogen research overview). However, translating kinase inhibition from oncology to infectious disease contexts must consider tissue specificity, immune modulation, and safety, as well as pathogen-specific dynamics.

Research Support Resources

For experimental workflows targeting BMX kinase in host-pathogen or cancer models, researchers may utilize BMX-IN-1 (SKU A3260), a highly selective, irreversible BMX kinase inhibitor. BMX-IN-1 has demonstrated efficacy in inhibiting BMX-dependent phosphorylation events, cell cycle progression, and apoptosis induction in cancer and infectious disease models. Detailed protocol guidance and benchmarking data are available from APExBIO and in recent literature. Researchers are advised to optimize dosing and storage conditions for their application, and to consult internal resources for troubleshooting and experimental design support.